ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector
ESGパフォーマンス、債務ファイナンス、研究開発成果：ヘルスケアセクターからの証拠 (AI 翻訳)
Sarmad Ali, O. Ciani, S. Ghislandi
🤖 gxceed AI 要約
日本語
この研究は、ヘルスケアセクターにおけるESGパフォーマンスが研究開発（R&D）成果に与える影響を分析し、債務ファイナンスが媒介・調整役を果たすことを明らかにした。2016年から2022年の欧州・米国の企業データを用いた実証分析により、ESGパフォーマンスはR&D成果を促進するが、高債務水準はその効果を弱めることが示された。さらに、EUのCSRDなどの制度的条件がESGの効果を強めることが分かった。
English
This study examines how ESG performance affects R&D output in healthcare, focusing on debt financing as a mediator and moderator. Using panel data from European and US firms (2016-2022), it finds that ESG performance promotes R&D output, but high debt levels weaken this effect. Institutional conditions like the EU CSRD enhance ESG's impact, with stronger effects in Europe and in biotech/pharma subsectors.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
日本の文脈では、ESGとR&Dの関係が債務水準により変化する点は、日本企業のガバナンス改革やESG統合において示唆に富む。特にヘルスケアセクターでのイノベーション促進には、過度な借入を避けつつESGを活用する戦略が重要となる。
In the global GX context
The study provides evidence that ESG performance enhances R&D output, moderated by debt. It underscores the importance of regulatory frameworks like the EU CSRD in amplifying ESG benefits. For global practitioners, it highlights the need to balance sustainability investments with financial leverage.
👥 読者別の含意
🔬研究者:This paper offers a nuanced view of the ESG-R&D link with debt financing as a mechanism, useful for corporate finance and sustainability scholars.
🏢実務担当者:Healthcare firms can use these findings to structure their ESG strategies and debt levels to maximize innovation outcomes.
🏛政策担当者:Policymakers can note that mandatory sustainability reporting (CSRD) may enhance the real effects of ESG on corporate innovation.
📄 Abstract（原文）
Amid growing calls for sustainability in the healthcare sector, this study examines how and under what conditions environmental, social, and governance (ESG) performance influences research and development (R&D) output. Although existing studies suggest that ESG performance enhances R&D output, the financial mechanisms that enable or constrain this relationship remain underexplored. We address this gap by theorizing and testing the dual role of debt financing as both a mediator and a moderator in the ESG performance and R&D output relationship within the healthcare sector, where innovation is highly capital‐intensive and socially consequential. Integrating stakeholder theory and agency theory, we argue that ESG performance promotes R&D output through improved access to reputational and financial resources, whereas high debt levels weaken this effect due to agency conflicts. Using panel data from 2016 to 2022 on healthcare firms in Europe and the United States, we estimate our main models using OLS and applying instrumental variable and system GMM techniques as robustness checks to address endogeneity. Our findings show that debt financing partially mediates the ESG–R&D link and negatively moderates it, revealing its ambivalent role. Compared to existing studies, our findings indicate that the effects of ESG performance on R&D output are conditional and context specific, with stronger impacts observed in Europe than in the United States, reflecting institutional conditions such as stricter European Union sustainability reporting frameworks, notably the Corporate Sustainability Reporting Directive (CSRD), along with robust policy incentives and longer term investment horizons. We also find pronounced effects in the biotechnology and pharmaceutical subsectors. This study contributes to theory by bridging competing views on ESG performance and offering a more nuanced understanding of how debt financing shapes the ESG–R&D output relationship.
🔗 Provenance — このレコードを発見したソース
- semanticscholar https://doi.org/10.1002/bse.70522first seen 2026-07-01 06:01:31
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。